about
Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor AgonistsComparative analysis of the cardioprotective properties of opioid receptor agonists in a rat model of myocardial infarction.Prospects for Creation of Cardioprotective Drugs Based on Cannabinoid Receptor Agonists.Specific features of adaptation of rats to chronic cold treatment.Receptor specificity of the antiarrhythmic effect produced by opioid peptides Dalargin and DADLE during myocardial reperfusion.Contribution of Opioid Receptors to the Cytoprotective Effect of the Adaptation to Chronic Hypoxia at Anoxia/Reoxygenation of Isolated Cardiomyocytes.Myocardial resistance to ischemic and reperfusion injuries under conditions of chronic administration of opioid receptor agonists and antagonists.The Role of Endogenous Opioid System in the Regulation of Heart Tolerance to Stress-Induced Damage.Preserved cardiac mitochondrial function and reduced ischaemia/reperfusion injury afforded by chronic continuous hypoxia: role of opioid receptors.Effect of stress adaptation on cyclic nucleotide content in myocardial tissue during acute ischemia/reperfusion.Role of ATP-Sensitive K+ Channels in Myocardial Infarct Size-Limiting Effect of Chronic Continuous Normobaric Hypoxia.Effect of Hypoxic Preconditioning on Stress Reaction in Rats.Functional state of myocardial mitochondria in ischemia reperfusion of the heart in rats adapted to hypoxia.Involvement of Autonomic Nervous System in Antiarrhythmic Effect of Intermittent Hypobaric Hypoxia.Role of protein kinase C, PI3 kinase, tyrosine kinases, NO-synthase, KATP channels and MPT pore in the signaling pathway of the cardioprotective effect of chronic continuous hypoxiaAntihypoxic, cardioprotective, and antifibrillation effects of a combined adaptogenic plant preparationIs oxidative stress of adipocytes a cause or a consequence of the metabolic syndrome?Pharmacology of mitochondrial permeability transition pore inhibitorsTakotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis
P50
Q28066192-063CC469-0180-4B4B-A562-14109CD83387Q34684375-8D9A3AD5-0A92-422E-9057-9027B7697FB2Q38612812-4B8CBB3E-10BC-49B3-86D7-6CEAA4F6BD04Q39206157-E01D8D86-424B-46CC-9C9A-760344651401Q44068815-0F9A0CCE-F505-4EEE-87FA-532592FEE3D3Q44330239-D1104BEA-859C-4AD0-8710-6DAC6DF5190FQ44341093-850E8187-1F3E-44E3-8746-94C413893B70Q44346224-31A96895-C68B-4CD6-910B-DAF4814695ABQ44349980-5ACCB82E-AEC3-4DE1-AE5F-6713FB9F7412Q46162246-FEFE6F7B-0305-49E4-B5E1-68365D882D6FQ47208633-50CF5505-B7B4-4B5D-A2C3-65A959054269Q51593809-63E476A1-C33A-4A5E-82FF-9CE013921B58Q51727475-C333B8A5-663A-4B04-A2CE-CA503A31AE52Q54457267-A7643899-D245-43D3-BED9-3DF867084F4EQ57300653-CB6792C5-5E10-4CC9-A1BC-1354259C52AEQ58232811-BE1F572C-CABB-4121-85AE-4000D21DC322Q59330292-E574414E-7789-4AF1-80EC-31E2947D2B0EQ91860378-BB8911F2-3A34-4FE0-80A4-DD41AD254A98Q93028630-212E108D-D721-4D6F-970B-64EEA10639BB
P50
description
researcher ORCID ID = 0000-0003-2264-1928
@en
wetenschapper
@nl
name
Natalia Naryzhnaya
@ast
Natalia Naryzhnaya
@en
Natalia Naryzhnaya
@es
Natalia Naryzhnaya
@nl
type
label
Natalia Naryzhnaya
@ast
Natalia Naryzhnaya
@en
Natalia Naryzhnaya
@es
Natalia Naryzhnaya
@nl
prefLabel
Natalia Naryzhnaya
@ast
Natalia Naryzhnaya
@en
Natalia Naryzhnaya
@es
Natalia Naryzhnaya
@nl
P1053
F-5310-2017
P106
P21
P31
P3829
P496
0000-0003-2264-1928